Aspectos epidemiológicos, clínicos e terapêuticos e o uso de natalizumabe em pacientes com esclerose múltipla - revisão

• DOI: https://doi.org/10.22533/at.ed.3542523043

• Palavras-chave: Esclerose múltipla, Natalizumabe, Tratamento;

• Keywords: Key-Words: Multiple sclerosis, Nataliumab, Treatment

• Abstract: Multiple sclerosis (MS) is a progressive disease that is difficult to predict, resulting in cases of disability and/or physical, psychological and social limitations. Currently, the tendency is to treat the patient early with highly effective therapy, as these are beneficial in controlling disease activity and crucial to avoid progressive disability. Natalizumab is one of the highly effective drugs and is associated with benefits in high-activity disease, despite safety observations.  The choice of disease-modifying therapy is a challenge in clinical practice, and should be discussed further, and clinical and radiological factors should be evaluated, as well as the JCV index for individualized treatment. The objective of this study is to present the epidemiological, clinical and therapeutic aspects and the use of natalizumab in patients with multiple sclerosis. Knowing the epidemiological, clinical and therapeutic aspects associated with the patient's individual characteristics is fundamental in deciding on treatment.